North America biodefense market is expected to grow by 5.3% annually in the forecast period and reach $10.07 billion by 2030 amid the COVID-19 pandemic.
Highlighted with 25 tables and 37 figures, this 103-page report “North America Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
Based on Product, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines
Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
Antibiotics
Masks
Other Products
Based on Sales Channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Online Sales
• Offline Sales
Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Military
• Civilian
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
